Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Clene Inc. (CLNN) Message Board

New Study to Explore the Link Between Sleep Disord

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 151
(Total Views: 91)
Posted On: 01/30/2025 5:21:11 PM
Avatar
Posted By: NetworkNewsWire
New Study to Explore the Link Between Sleep Disorder and Parkinson’s

Funded by the U.S. Department of Defense, a new study will be conducted to examine why individuals, especially veterans, who suffer from a certain sleep disorder often end up developing Parkinson’s disease. The DoD awarded $4 million to researchers at Oregon Health and Science University (OSHU), the VA Healthcare System at Portland, the VA Sound Healthcare System at Puget, and the University of Washington to conduct this study.

The research aims to establish why most people who develop a sleep disorder that causes them to thrash in their sleep later develop Parkinson’s. The team wants to know why this happens and if anything can be done to cut the risk of Parkinson’s disease developing in this high risk group. The recruitment process has started.

The researchers believe that the answers they seek can be found in the glymphatic system. This system is most active during REM sleep, or very deep sleep. The glymphatic system exists throughout the brain and is responsible for clearing metabolic waste and proteins from the brain. Dr. Miranda Lim, PhD., explains that the study seeks to find ways to boost how the glymphatic system works. She adds that to do this, they must first understand how this vital system works.

To this end, the team will require three categories of study subjects. The first group will be individuals that suffer from Parkinson’s disease. The second group will be individuals diagnosed with the sleep disorder which seems to be the precursor of Parkinson’s. The final group will be composed of healthy subjects that will serve as the control group. All these selected people will be subjected to MRI tests to study their brains.

REM sleep, or rapid eye movement sleep, is a deep form of sleep characterized by near paralysis of the muscles in the body. For individuals afflicted with RBD (rapid eye movement sleep behavioral disorder), this muscle paralysis doesn’t happen as it should. As a result, individuals with this disorder act while they dream, and this often causes them to injure themselves or others, such as their partners. This explains why boosting the function of the glymphatic system could have profound benefits by not only addressing the sleeping disorder but also potentially forestalling the onset of Parkinson’s in the affected individuals.

The study will involve three different projects happening simultaneously. One project will involve studying glymphatic function in healthy individuals, in individuals with Parkinson’s, and in people with the sleep disorder. The second project entails studying mice treated with a high BP drug often prescribed to some people with nightmares resulting from PTSD. The objective here is to see whether that drug helps the brain to clear proteins called Lewy bodies. The third project entails studying the brain tissues of people who died and were known to suffer from Parkinson’s disease.

The study is expected to be completed in about 4 years. The findings of this study could enrich the scientific data available to enterprises like Clene Inc. (NASDAQ: CLNN) that are focused on finding effective treatments targeting neurodegenerative conditions like Parkinson’s disease.

NOTE TO INVESTORS: The latest news and updates relating to Clene Inc. (NASDAQ: CLNN) are available in the company’s newsroom at https://ibn.fm/CLNN

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer



(0)
(0)




Clene Inc. (CLNN) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us